Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC.CRL · Entity 3398 | Corporate Executive VP & CCO | November 07, 2024 | November 08, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Report date November 07, 2024 · Filed November 08, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 23,337 |
Reported balance
After 2024-11-07 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2024-11-07 · Gift · Disposed 470 · Balance 23,337 F1: Reflects the exempt transfer pursuant to Rule 16a-13 of 965 shares held by the reporting person to William D. Barbo Revocable Trust. |
| Common StockSEC Table I · non-derivative | Direct | 2,468 |
Reported balance
Holding disclosure · report date 2024-11-07 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 2,468 |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the exempt transfer pursuant to Rule 16a-13 of 965 shares held by the reporting person to William D. Barbo Revocable Trust.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 07, 2024 Filed Nov 8, 2024 23:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GiftCommon Stock | 470 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-026871 · form4.xml · nonDerivative · entry 2 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 23,337 F1 · balance_after: Reflects the exempt transfer pursuant to Rule 16a-13 of 965 shares held by the reporting person to William D. Barbo Revocable Trust. Read SEC document |
| May 29, 2024 Filed May 31, 2024 00:05 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 179 | $214.51 | $38,397.29 |
DisclosureSEC source: 0001127602-24-017059 · form4.xml · nonDerivative · entry 1 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,433 Read SEC document |
| May 28, 2024 Filed May 28, 2024 21:42 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 84 | $217.21 | $18,245.64 |
DisclosureSEC source: 0001127602-24-016732 · form4.xml · nonDerivative · entry 4 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,605 Read SEC document |
| May 28, 2024 Filed May 30, 2024 23:47 UTC Amendment | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 99 | $217.21 | $21,503.79 |
DisclosureSEC source: 0001127602-24-017041 · form4a.xml · nonDerivative · entry 4 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,612 Read SEC document |
| May 27, 2024 Filed May 28, 2024 21:42 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 132 | $217.21 | $28,671.72 |
DisclosureSEC source: 0001127602-24-016732 · form4.xml · nonDerivative · entry 3 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,689 Read SEC document |
| May 27, 2024 Filed May 30, 2024 23:47 UTC Amendment | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 147 | $217.21 | $31,929.87 |
DisclosureSEC source: 0001127602-24-017041 · form4a.xml · nonDerivative · entry 3 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,711 Read SEC document |
| May 26, 2024 Filed May 28, 2024 21:42 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 177 | $217.21 | $38,446.17 |
DisclosureSEC source: 0001127602-24-016732 · form4.xml · nonDerivative · entry 2 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,821 Read SEC document |
| May 26, 2024 Filed May 30, 2024 23:47 UTC Amendment | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 177 | $217.21 | $38,446.17 |
DisclosureSEC source: 0001127602-24-017041 · form4a.xml · nonDerivative · entry 2 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,858 Read SEC document |
| February 22, 2024 Filed Feb 23, 2024 21:57 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 4,050 | $248.50 | $1,006,425.00 |
DisclosureSEC source: 0001127602-24-006706 · form4.xml · nonDerivative · entry 1 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 22,879 F1 · balance_after: Reflects the exempt transfer pursuant to Rule 16a-13 of 7,547 shares held by the reporting person to William D. Barbo Revocable Trust. Read SEC document |
| January 29, 2024 Filed Jan 31, 2024 22:23 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 770 | $220.28 | $169,615.60 |
DisclosureSEC source: 0001127602-24-002794 · form4.xml · nonDerivative · entry 3 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,330 Read SEC document |
| January 29, 2024 Filed Jan 31, 2024 22:23 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 2,997 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-002794 · form4.xml · nonDerivative · entry 2 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,100 F1 · shares: Reflects shares of common stock issued following the achievement of performance goals set forth in performance share unit awards originally granted on May 28, 2021. Read SEC document |
| January 29, 2024 Filed Mar 25, 2024 22:48 UTC Amendment | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 744 | $220.28 | $163,888.32 |
DisclosureSEC source: 0001127602-24-011121 · form4a.xml · nonDerivative · entry 3 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,293 Read SEC document |
| January 29, 2024 Filed Mar 25, 2024 22:48 UTC Amendment | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 2,934 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-011121 · form4a.xml · nonDerivative · entry 2 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,037 F1 · shares: Reflects shares of common stock issued following the achievement of performance goals set forth in performance share unit awards originally granted on May 28, 2021. Read SEC document |
| August 10, 2023 Filed Aug 14, 2023 20:17 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionStock Options (Right to Buy) · Derivative | 5,511 | $0.00 Strike: $144.67 | $0.00 |
DisclosureSEC source: 0001127602-23-022488 · form4.xml · derivative · entry 4 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,511 shares Expires 2024-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 10, 2023 Filed Aug 14, 2023 20:17 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 5,511 | $144.67 | $797,276.37 |
DisclosureSEC source: 0001127602-23-022488 · form4.xml · nonDerivative · entry 3 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,103 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 10, 2023 Filed Aug 14, 2023 20:17 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 5,763 | $217.24 | $1,251,954.12 |
DisclosureSEC source: 0001127602-23-022488 · form4.xml · nonDerivative · entry 2 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,592 Read SEC document |
| May 29, 2023 Filed May 31, 2023 17:27 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 202 | $194.12 | $39,212.24 |
DisclosureSEC source: 0001127602-23-017135 · form4.xml · nonDerivative · entry 4 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,954 Read SEC document |
| May 28, 2023 Filed May 31, 2023 17:27 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 112 | $194.12 | $21,741.44 |
DisclosureSEC source: 0001127602-23-017135 · form4.xml · nonDerivative · entry 3 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,156 Read SEC document |
| May 27, 2023 Filed May 31, 2023 17:27 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 166 | $194.12 | $32,223.92 |
DisclosureSEC source: 0001127602-23-017135 · form4.xml · nonDerivative · entry 2 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,268 Read SEC document |
| May 26, 2023 Filed May 31, 2023 17:27 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantStock Options (Right to Buy) · Derivative | 4,696 | $194.12 Strike: $194.12 | $911,587.52 |
DisclosureSEC source: 0001127602-23-017135 · form4.xml · derivative · entry 5 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,696 Underlying: Common Stock · 4,696 shares Expires 2033-05-26 F2 · shares: Stock Options vest as follows: 1,174 on May 26, 2024, 1,174 on May 26, 2025, 1,174 on May 26, 2026 and 1,174 on May 26, 2027. Read SEC document |
| May 26, 2023 Filed May 31, 2023 17:27 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 1,958 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-017135 · form4.xml · nonDerivative · entry 1 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,434 F1 · shares: Restricted Stock Units vest as follows: 489 on May 26, 2024, 489 on May 26, 2025, 490 on May 26, 2026 and 490 on May 26, 2027. Read SEC document |
| February 22, 2023 Filed Feb 22, 2023 21:29 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 287 | $243.60 | $69,913.20 |
DisclosureSEC source: 0001127602-23-006469 · form4.xml · nonDerivative · entry 1 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,476 Read SEC document |
| January 27, 2023 Filed Jan 30, 2023 21:48 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 2,897 | $244.29 | $707,708.13 |
DisclosureSEC source: 0001127602-23-002678 · form4.xml · nonDerivative · entry 2 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,763 Read SEC document |
| January 27, 2023 Filed Jan 30, 2023 21:48 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 7,857 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-002678 · form4.xml · nonDerivative · entry 1 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,660 F1 · shares: Reflects shares of common stock issued following the achievement of performance goals set forth in performance share unit awards originally granted on May 29, 2020. Read SEC document |
| December 02, 2022 Filed Dec 6, 2022 21:40 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionStock Options · Derivative | 3,205 | $0.00 Strike: $109.34 | $0.00 |
DisclosureSEC source: 0000950103-22-020817 · dp185494_4-barbo.xml · derivative · entry 9 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,205 shares Expires 2023-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 02, 2022 Filed Dec 6, 2022 21:40 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 700 | $221.08 | $154,753.27 |
DisclosureSEC source: 0000950103-22-020817 · dp185494_4-barbo.xml · nonDerivative · entry 8 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,803 F4 · price: This transaction was executed in multiple trades at prices ranging from $220.93 to $221.32. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 02, 2022 Filed Dec 6, 2022 21:40 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 1,226 | $220.14 | $269,891.52 |
DisclosureSEC source: 0000950103-22-020817 · dp185494_4-barbo.xml · nonDerivative · entry 7 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,503 F3 · price: This transaction was executed in multiple trades at prices ranging from $219.90 to $220.34. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 02, 2022 Filed Dec 6, 2022 21:40 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 873 | $219.41 | $191,548.51 |
DisclosureSEC source: 0000950103-22-020817 · dp185494_4-barbo.xml · nonDerivative · entry 6 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,729 F2 · price: This transaction was executed in multiple trades at prices ranging from $218.92 to $219.83. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 02, 2022 Filed Dec 6, 2022 21:40 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 406 | $218.28 | $88,620.79 |
DisclosureSEC source: 0000950103-22-020817 · dp185494_4-barbo.xml · nonDerivative · entry 5 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,602 F1 · price: This transaction was executed in multiple trades at prices ranging from $217.89 to $218.875. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 02, 2022 Filed Dec 6, 2022 21:40 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 3,205 | $109.34 | $350,434.70 |
DisclosureSEC source: 0000950103-22-020817 · dp185494_4-barbo.xml · nonDerivative · entry 4 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,008 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2022 Filed Dec 6, 2022 21:40 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GiftCommon Stock | 200 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-22-020817 · dp185494_4-barbo.xml · nonDerivative · entry 3 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 19,035 Read SEC document |
| June 07, 2022 Filed Dec 6, 2022 21:40 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GiftCommon Stock | 391 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-22-020817 · dp185494_4-barbo.xml · nonDerivative · entry 2 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 19,235 Read SEC document |
| June 07, 2022 Filed Dec 6, 2022 21:40 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GiftCommon Stock | 391 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-22-020817 · dp185494_4-barbo.xml · nonDerivative · entry 1 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,803 Read SEC document |
| May 29, 2022 Filed Jun 1, 2022 21:14 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 202 | $244.41 | $49,370.82 |
DisclosureSEC source: 0001127602-22-016208 · form4.xml · nonDerivative · entry 5 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,194 Read SEC document |
| May 28, 2022 Filed Jun 1, 2022 21:14 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 112 | $244.41 | $27,373.92 |
DisclosureSEC source: 0001127602-22-016208 · form4.xml · nonDerivative · entry 4 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,396 Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 21:14 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantStock Options (Right to Buy) · Derivative | 4,036 | $244.41 Strike: $244.41 | $986,438.76 |
DisclosureSEC source: 0001127602-22-016208 · form4.xml · derivative · entry 6 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,036 Underlying: Common Stock · 4,036 shares Expires 2032-05-27 F2 · shares: Stock Options vest as follows: 1,009 on May 27, 2023, 1,009 on May 27, 2024, 1,009 on May 27, 2025 and 1,009 on May 27, 2026. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 21:14 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 1,493 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-016208 · form4.xml · nonDerivative · entry 3 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,508 F1 · shares: Unvested restricted stock units vest as follows: 373 on May 27, 2023, 373 on May 27, 2024, 373 on May 27, 2025 and 374 on May 27, 2026. Read SEC document |
| March 11, 2022 Filed Jun 1, 2022 21:14 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GiftCommon Stock | 754 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-016208 · form4.xml · nonDerivative · entry 2 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 18,844 Read SEC document |
| March 11, 2022 Filed Jun 1, 2022 21:14 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GiftCommon Stock | 754 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-016208 · form4.xml · nonDerivative · entry 1 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,015 Read SEC document |
| February 23, 2022 Filed Feb 23, 2022 21:13 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 315 | $289.58 | $91,217.70 |
DisclosureSEC source: 0001127602-22-006261 · form4.xml · nonDerivative · entry 4 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,769 Read SEC document |
| February 22, 2022 Filed Feb 23, 2022 21:13 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 287 | $293.61 | $84,266.07 |
DisclosureSEC source: 0001127602-22-006261 · form4.xml · nonDerivative · entry 3 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,084 Read SEC document |
| February 08, 2022 Filed Feb 23, 2022 21:13 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GiftCommon Stock | 6,178 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-006261 · form4.xml · nonDerivative · entry 2 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 18,090 Read SEC document |
| February 08, 2022 Filed Feb 23, 2022 21:13 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GiftCommon Stock | 6,178 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-006261 · form4.xml · nonDerivative · entry 1 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,371 Read SEC document |
| January 28, 2022 Filed Feb 1, 2022 22:35 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 4,095 | $312.24 | $1,278,622.80 |
DisclosureSEC source: 0001127602-22-002797 · form4.xml · nonDerivative · entry 3 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,549 Read SEC document |
| January 28, 2022 Filed Feb 1, 2022 22:35 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 10,273 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-002797 · form4.xml · nonDerivative · entry 2 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,644 F1 · shares: Reflects shares of common stock issued following the achievement of performance goals set forth in performance share unit awards originally granted on February 22, 2019. Read SEC document |
| December 01, 2021 Filed Feb 1, 2022 22:35 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GiftCommon Stock | 400 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-002797 · form4.xml · nonDerivative · entry 1 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 11,912 Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 15:52 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionStock Options (Right to Buy) · Derivative | 1,513 | $0.00 Strike: $179.66 | $0.00 |
DisclosureSEC source: 0001127602-21-023431 · form4.xml · derivative · entry 17 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,541 Underlying: Common Stock · 1,513 shares Expires 2030-05-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 15:52 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionStock Options (Right to Buy) · Derivative | 2,755 | $0.00 Strike: $144.67 | $0.00 |
DisclosureSEC source: 0001127602-21-023431 · form4.xml · derivative · entry 16 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,511 Underlying: Common Stock · 2,755 shares Expires 2024-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 15:52 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionStock Options (Right to Buy) · Derivative | 3,204 | $0.00 Strike: $109.34 | $0.00 |
DisclosureSEC source: 0001127602-21-023431 · form4.xml · derivative · entry 15 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,205 Underlying: Common Stock · 3,204 shares Expires 2023-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 15:52 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 200 | $409.08 | $81,816.00 |
DisclosureSEC source: 0001127602-21-023431 · form4.xml · nonDerivative · entry 14 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,371 F1 · balance_after: 4,915 shares were transferred from Trust to Direct Holdings. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.